Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/197660
Title: Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richter's Transformation
Author: Ortiz-Maldonado Gibson, Valentín
Frigola, Gerard
Español Rego, Marta
Balagué, Olga
Martínez Cibrian, Nuria
Magnano, Laura
Giné Soca, Eva
Pascal i Capdevila, Mariona
Correa, Juan G.
Martínez Roca, Alexandra
Cid, Joan
Lozano Molero, Miguel
Villamor i Casas, Neus
Benitez Ribas, Daniel
Esteve Comas, Jordi
López Guillermo, Armando
Campo Güerri, Elias
Urbano Ispizua, Álvaro
Juan, Manel
Delgado, Julio (Delgado González)
Keywords: Leucèmia limfocítica crònica
Teràpia cel·lular
Chronic lymphocytic leukemia
Cellular therapy
Issue Date: 31-Jan-2022
Abstract: CART19 cells are emerging as an alternative therapy for patients with chronic lymphocytic leukemia (CLL). Here we report the outcome of nine consecutive patients with CLL treated with ARI-0001 CART19 cells, six of them with Richter’s transformation (RT). One patient with RT never received therapy. The cytokine release syndrome rate was 87.5% (12.5% grade ≥3). Neurotoxicity was not observed in any patient. All patients experienced absolute B-cell aplasia, and seven (87.5%) responded to therapy. With a median follow-up of 5.6 months, two patients with RT experienced a CD19-negative relapse. In conclusion, ARI-0001 cell therapy was feasible, safe, and effective in patients with high risk CLL or RT
Note: Reproducció del document publicat a: https://doi.org/10.3389/fonc.2022.828471
It is part of: Frontiers In Oncology, 2022, vol.12, num. 828471
URI: http://hdl.handle.net/2445/197660
Related resource: https://doi.org/10.3389/fonc.2022.828471
ISSN: 2234-943X
Appears in Collections:Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Medicina)



This item is licensed under a Creative Commons License Creative Commons